AZNAstraZenecaRunning, no new patients
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NSCLC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,350 (final count)
- Started
- Dec 29, 2022
- Main results expected
- Nov 1, 2027
- Fully finished
- Nov 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population
Measured over: Approximately 3 years
Overall Survival (OS) in the non-squamous TROP2 biomarker positive population
Measured over: Approximately 5 years
PFS by BICR in the non-squamous population
Measured over: Approximately 3 years
OS in the non-squamous population
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05687266 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC